Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 12/2013

01-12-2013 | Clinical Guides in Oncology

SEOM clinical guidelines for the treatment of osteosarcoma in adults-2013

Authors: A. Redondo, J. Cruz, A. Lopez-Pousa, F. Barón

Published in: Clinical and Translational Oncology | Issue 12/2013

Login to get access

Abstract

The diagnosis and treatment of osteosarcoma should be performed by an experienced multidisciplinary team. Considering it is a systemic disease, chemotherapy is essential for long-term success. The drugs most commonly used are: cisplatin, adriamycin, high-dose methotrexate, ifosfamide, etoposide, and, more recently, mifamurtide. The neoadjuvant chemotherapy allows to know tumour chemosensitivity and getting the main prognostic factor: the percentage of tumour necrosis. In addition to chemotherapy, it is important to conduct surgical resection of primary tumour with wide margins, and in disseminated disease also to attempt resection of pulmonary metastasis.
Appendix
Available only for authorised users
Literature
1.
Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program. Cancer. 2009;115(7):1531–43.PubMedCrossRef
2.
Wittig JC, Bickels J, Prebat D, Jelinek J, Kellar-Graney K, Shmookler B, et al. Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. Am Fam Physician. 2002;65:1123–32.PubMed
3.
Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop. 1980;153:106–20.PubMed
4.
Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776–90.PubMedCrossRef
5.
Hogerndoorn PCW. Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;5:v204–13.CrossRef
6.
Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986;314(25):1600–6.PubMedCrossRef
7.
Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival––a report from the children’s oncology group. J Clin Oncol. 2008;26(4):633–8.PubMedCrossRef
8.
Ferrari S, Ruggieri P, Cefalo G, Tamburini A, Capanna R, Fagioli F, et al. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in non-metastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. J Clin Oncol. 2012;30(17):2112–8.PubMedCrossRef
9.
Bacci G, Picci P, Ferrari S, Ruggieri P, Casadei R, Tienghi A, et al. Primary chemotherapy and delayed surgery for non metastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer. 1993;72(11):3227–38.PubMedCrossRef
10.
Winkler K, Beron G, Delling G, Heise U, Kabisch H, Purfürst C, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol. 1988;6(2):329–37.PubMed
11.
Bacci G, Rocca M, Salone M, Balladelli A, Ferrari S, Palmerini E, et al. High grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions. J Surg Oncol. 2008;98(6):415.PubMedCrossRef
12.
Kager L, Zoubek A, Potschger U, Kastner U, Flege S, Kempf-Bielack B, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2003;21:2011–8.PubMedCrossRef
13.
Mineo TC, Ambrogi V, Pompeo E, Nofroni I. The value of the Nd:YAG laser for the surgery of lung metastases in a randomized trial. Chest. 1998;113:1402–7.PubMedCrossRef
14.
Gentet JC, Brunat-Mentigny M, Demaille MC, Pein F, Avet-Loiseau H, Berger C, et al. Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French society of paediatric oncology. Eur J Can. 1997;33(2):232–7.CrossRef
15.
Navid F, Willert JR, McCarville MB, Furman W, Watkins A, Roberts W, et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer. 2008;113:419–25.PubMedCrossRef
16.
Saylors RL III, Stine KC, Sullivan J, Kepner JL, Wall DA, Bernstein ML, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a paediatric oncology group phase II study. J Clin Oncol. 2001;19:3463–9.PubMed
17.
Chawla SP, Staddon AP, Baker LH, Schuetze SM, Tolcher AW, D’Amato GZ, et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol. 2012;30(1):78–84.PubMedCrossRef
18.
Grignani G, Palmerini E, Dileo P, Asaftei SD, D’Ambrosio L, Pignochino Y, et al. A phase II trial of sorafenib in relapsed and un resectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian sarcoma group study. Ann Oncol. 2012;23(2):508–16.PubMedCrossRef
19.
Bielack SS, Kempf-Bielack B, Heise U, Schwenzer D, Winkler K, et al. Combined modality treatment for osteosarcoma occurring as a second malignant disease. J Clin Oncol. 1999;17:1164–74.PubMed
Metadata
Title
SEOM clinical guidelines for the treatment of osteosarcoma in adults-2013
Authors
A. Redondo
J. Cruz
A. Lopez-Pousa
F. Barón
Publication date
01-12-2013
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 12/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-013-1087-0

Other articles of this Issue 12/2013

Clinical and Translational Oncology 12/2013 Go to the issue

Clinical Guides in Oncology

SEOM clinical guidelines for the management of metastatic breast cancer 2013

Clinical Guides in Oncology

SEOM guide to antiemetic prophylaxis in cancer patients treated with chemotherapy 2013

Clinical Guides in Oncology

SEOM clinical guidelines for the treatment of nasopharyngeal carcinoma 2013

Clinical Guides in Oncology

SEOM clinical guidelines for the treatment of small-cell lung cancer 2013

Clinical Guides in Oncology

SEOM Clinical Guidelines for the systemic treatment of early breast cancer 2013

Clinical Guides in Oncology

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2013
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits